Across diverse therapeutic areas, from hormone‐dependent cancers and hematologic malignancies to inflammatory diseases and neurodegenerative conditions, PROTACs have consistently demonstrated their unique ability to target previously “undruggable” proteins, including transcription factors like STAT3 and MYC [449], mutant oncoproteins such as KRAS G12C and BRAF V600E, and scaffolding proteins that lack conventional binding pockets [450]. This evidence concerns the gene BRAF and hematologic disorder.